



## Spruce Biosciences to Participate in March Investor Conferences

March 1, 2022

SAN FRANCISCO--(BUSINESS WIRE)--Mar. 1, 2022-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place virtually in March.

- **Cowen 42<sup>nd</sup> Annual Health Care Conference**

**Date:** March 7-9, 2022

**Format:** [Company presentation](#) (March 9 at 11:10 a.m. ET) and 1x1 meetings

- **Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference**

**Date:** March 15-17, 2022

**Format:** [Fireside chat](#) (March 16 at 8:00 a.m. ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the [Events](#) section of the company's investor relations website at <https://investors.sprucebiosciences.com>. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

### About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit [www.sprucebiosciences.com](http://www.sprucebiosciences.com) and follow us on Twitter [@Spruce\\_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20220301005046/en/>

### Media Contact

Will Zasadny  
Canale Communications  
(619) 961-8848  
[will.zasadny@canalecomm.com](mailto:will.zasadny@canalecomm.com)  
[media@sprucebiosciences.com](mailto:media@sprucebiosciences.com)

### Investors

Xuan Yang  
Solebury Trout  
(415) 971-9412  
[xyang@soleburytrout.com](mailto:xyang@soleburytrout.com)  
[investors@sprucebiosciences.com](mailto:investors@sprucebiosciences.com)

Source: Spruce Biosciences, Inc.